MEREO BIOPHARMA GROUP PLC Number Of Share Options Exercisable In Share-based Payment Arrangement
MEREO BIOPHARMA GROUP PLC (MREO) had Number Of Share Options Exercisable In Share-based Payment Arrangement of 787453000.00% as of 2022-12-31, per its 20-F filed 2023-03-28.
Discontinued › Notes › Compensation Related Costs
ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement · last filed 2023-03-28
- 2022-12-31: Number Of Share Options Exercisable In Share-based Payment Arrangement 787453000.00%.
- 2021-12-31: Number Of Share Options Exercisable In Share-based Payment Arrangement 829769400.00%.
- 2020-12-31: Number Of Share Options Exercisable In Share-based Payment Arrangement 892360000.00%.
| Period end | Number Of Share Options Exercisable In Share-based Payment Arrangement |
|---|---|
| 2022-12-31 | 787453000.00% 20-F · filed 2023-03-28 |
| 2021-12-31 | 829769400.00% 20-F · filed 2023-03-28 |
| 2020-12-31 | 892360000.00% 20-F · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |